|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Scher HI, Beer TM, Higano CS, Anand A,
Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J,
et al Prostate Cancer Foundation/Department of Defense Prostate
Cancer Clinical Trials Consortium: Antitumour activity of MDV3100
in castration-resistant prostate cancer: A phase 1–2 study. Lancet.
375:1437–1446. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Culig Z, Klocker H, Bartsch G and Hobisch
A: Androgen receptors in prostate cancer. Endocr Relat Cancer.
9:155–170. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Heinlein CA and Chang C: Androgen receptor
in prostate cancer. Endocr Rev. 25:276–308. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen Y, Clegg NJ and Scher HI:
Anti-androgens and androgen-depleting therapies in prostate cancer:
New agents for an established target. Lancet Oncol. 10:981–991.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Montgomery RB, Mostaghel EA, Vessella R,
Hess DL, Kalhorn TF, Higano CS, True LD and Nelson PS: Maintenance
of intratumoral androgens in metastatic prostate cancer: A
mechanism for castration-resistant tumor growth. Cancer Res.
68:4447–4454. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Watson PA, Chen YF, Balbas MD, Wongvipat
J, Socci ND, Viale A, Kim K and Sawyers CL: Constitutively active
androgen receptor splice variants expressed in castration-resistant
prostate cancer require full-length androgen receptor. Proc Natl
Acad Sci USA. 107:16759–16765. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Díaz-Laviada I and Rodriguez-Henche N: The
potential antitumor effects of capsaicin. Progr Drug Res.
68:181–208. 2014.
|
|
9
|
Sánchez AM, Malagarie-Cazenave S, Olea N,
Vara D, Chiloeches A and Díaz-laviada I: Apoptosis induced by
capsaicin in prostate PC-3 cells involves ceramide accumulation,
neutral sphingomyelinase, and JNK activation. Apoptosis.
12:2013–2024. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jansson MD and Lund AH: MicroRnA and
cancer. Mol Oncol. 6:590–610. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Noonan EJ, Place RF, Basak S, Pookot D and
Li LC: miR-449a causes Rb-dependent cell cycle arrest and
senescence in prostate cancer cells. Oncotarget. 1:349–358.
2010.PubMed/NCBI
|
|
12
|
Noonan EJ, Place RF, Pookot D, Basak S,
Whitson JM, Hirata H, Giardina C and Dahiya R: miR-449a targets
HDAC-1 and induces growth arrest in prostate cancer. Oncogene.
28:1714–1724. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kusuda R, Cadetti F, Ravanelli MI, Sousa
TA, Zanon S, De Lucca FL and Lucas G: Differential expression of
microRNAs in mouse pain models. Mol Pain. 7:172011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gill R, Kuriakose R, Gertz ZM, Salloum FN,
Xi L and Kukreja RC: Remote ischemic preconditioning for myocardial
protection: Update on mechanisms and clinical relevance. Mol Cell
Biochem. 402:41–49. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jankovic B, Loblaw DA and Nam R: Capsaicin
may slow PSA doubling time: Case report and literature review. Can
Urol Assoc J. 4:E9–E11. 2010.PubMed/NCBI
|
|
16
|
Chakraborty S, Mazumdar M, Mukherjee S,
Bhattacharjee P, Adhikary A, Manna A, Chakraborty S, Khan P, Sen A
and Das T: Restoration of p53/miR-34a regulatory axis decreases
survival advantage and ensures Bax-dependent apoptosis of non-small
cell lung carcinoma cells. FEBS Lett. 588:549–559. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kaymaz BT, Cetintaş Kaymaz VB, Aktan C and
Kosova B: MicroRNA-520a-5p displays a therapeutic effect upon
chronic myelogenous leukemia cells by targeting STAT3 and enhances
the anticarcinogenic role of capsaicin. Tumour Biol. 35:8733–8742.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sánchez AM, Martínez-Botas J,
Malagarie-Cazenave S, Olea N, Vara D, Lasunción MA and Díaz-Laviada
I: Induction of the endoplasmic reticulum stress protein
gADD153/CHOP by capsaicin in prostate PC-3 cells: A microarray
study. Biochem Biophys Res Commun. 372:785–791. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mori A, Lehmann S, O’Kelly J, Kumagai T,
Desmond JC, Pervan M, McBride WH, Kizaki M and Koeffler HP:
Capsaicin, a component of red peppers, inhibits the growth of
androgen-independent, p53 mutant prostate cancer cells. Cancer Res.
66:3222–3229. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Venier NA, Colquhoun AJ, Sasaki H, Kiss A,
Sugar L, Adomat H, Fleshner NE, Klotz LH and Venkateswaran V:
Capsaicin: A novel radio-sensitizing agent for prostate cancer.
Prostate. 75:113–125. 2015. View Article : Google Scholar
|
|
21
|
Park M-T and Lee S-J: Cell cycle and
cancer. J Biochem Mol Biol. 36:60–65. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yamashita S, Lai KP, Chuang KL, Xu D,
Miyamoto H, Tochigi T, Pang ST, Li L, Arai Y, Kung HJ, et al:
ASC-J9 suppresses castration-resistant prostate cancer growth
through degradation of full-length and splice variant androgen
receptors. Neoplasia. 14:74–83. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lin TH, Lee SO, Niu Y, Xu D, Liang L, Li
L, Yeh SD, Fujimoto N, Yeh S and Chang C: Differential androgen
deprivation therapies with anti-androgens casodex/bicalutamide or
MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) lead
to promotion versus suppression of prostate cancer metastasis. J
Biol Chem. 288:19359–19369. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lin TH, Izumi K, Lee SO, Lin WJ, Yeh S and
Chang C: Anti-androgen receptor ASC-J9 versus anti-androgens
MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite
effects on prostate cancer metastasis via differential modulation
of macrophage infiltration and STAT3-CCL2 signaling. Cell Death
Dis. 4:e7642013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Solit DB, Zheng FF, Drobnjak M, Münster
PN, Higgins B, Verbel D, Heller G, Tong W, Cordon-Cardo C, Agus DB,
et al: 17-Allylamino-17-demethoxygeldanamycin induces the
degradation of androgen receptor and HER-2/neu and inhibits the
growth of prostate cancer xenografts. Clin Cancer Res. 8:986–993.
2002.PubMed/NCBI
|
|
26
|
Nadiminty N, Tummala R, Lou W, Zhu Y,
Zhang J, Chen X, eVere White RW, Kung HJ, Evans CP and Gao AC:
MicroRNA let-7c suppresses androgen receptor expression and
activity via regulation of Myc expression in prostate cancer cells.
J Biol Chem. 287:1527–1537. 2012. View Article : Google Scholar :
|
|
27
|
Epis MR, Giles KM, Barker A, Kendrick TS
and Leedman PJ: miR-331–3p regulates ERBB-2 expression and androgen
receptor signaling in prostate cancer. J Biol Chem.
284:24696–24704. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sikand K, Slaibi JE, Singh R, Slane SD and
Shukla GC: miR 488* inhibits androgen receptor
expression in prostate carcinoma cells. Int J Cancer. 129:810–819.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Östling P, Leivonen SK, Aakula A, Kohonen
P, Mäkelä R, Hagman Z, Edsjö A, Kangaspeska S, Edgren H, Nicorici
D, et al: Systematic analysis of microRNAs targeting the androgen
receptor in prostate cancer cells. Cancer Res. 71:1956–1967. 2011.
View Article : Google Scholar : PubMed/NCBI
|
